Last reviewed · How we verify
Suraxavir Marboxil
Suraxavir Marboxil is a prodrug of suraxavir, a nucleotide reverse transcriptase inhibitor.
Suraxavir Marboxil is a prodrug of suraxavir, a nucleotide reverse transcriptase inhibitor. Used for Treatment of HIV-1 infection.
At a glance
| Generic name | Suraxavir Marboxil |
|---|---|
| Sponsor | Jiangxi Kvvit Pharmaceutical Co., Ltd. |
| Drug class | Nucleotide reverse transcriptase inhibitor |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
Suraxavir Marboxil works by inhibiting the activity of the HIV reverse transcriptase enzyme, which is essential for the replication of retroviruses like HIV. This leads to a decrease in viral load and an increase in CD4 cell count.
Approved indications
- Treatment of HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Abdominal pain
Key clinical trials
- Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting (PHASE3)
- A Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Suraxavir Marboxil for Suspension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |